Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Akgun Ince (NPI 1053372334)

Field	Value
Entity Type	Individual
Organization	Akgun Ince
Address	522 N New Ballas Rd
City	Saint Louis
State	MO
ZIP	63141
Taxonomy	Rheumatology Physician
NPI Enumerated	March 28, 2006

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the available data: total Medicare revenue is $2.1M while there is no Medicaid billing on file, indicating Medicare drives the entirety of billed public-payer activity reported here. That concentration means Medicare reimbursement policy and Part B drug coverage are the primary determinants of the provider’s public-revenue performance.

Revenue is highly concentrated in a small set of biologic drug codes: the precomputed top three Medicare codes account for 79.1% of this provider's total Medicare revenue, led by J0129 (25.7K claims, $34 avg paid/claim, $872.1K revenue, 40.9%), J1745 (21.8K claims, $26 avg paid/claim, $566.8K revenue, 26.6%), and J3262 (62K claims, $4 avg paid/claim, $248.2K revenue, 11.6%). This concentration shows the practice’s revenue base is dominated by a handful of infused biologic therapies rather than distributed across many evaluation-and-management or ancillary services.

The mix of leading codes points to an infusion‑centric rheumatology practice: J0129 (abatacept), J1745 (infliximab), and J3262 (tocilizumab) are biologic infusions commonly used in inflammatory and autoimmune disease management, and the taxonomy is Rheumatology Physician. Combined with high utilization of infusion administration codes elsewhere on the profile, the operation appears oriented toward in‑office supervised infusion services rather than primarily office‑visit revenue.

On competitive standing, the provider is a national high-volume outlier for certain drugs: J1745 ranks #14 of 1352 providers nationally (99th percentile; extreme outlier), and J0129 ranks #73 of 1221 (94th percentile; notably above typical national volume). By contrast, J3262 ranks #164 of 618 (74th percentile; typical, unremarkable volume), indicating the practice is a major national player for infliximab and above‑typical for abatacept but only a routine participant for tocilizumab at the national level.

Infusion-service intensity is further underscored by procedure-level rankings: 96415 (the add-on code for each additional infusion hour) appears with $10.7K revenue and ranks #53 of 4959 providers nationally (99th percentile; extreme outlier), while 96365 (initial IV infusion) ranks #431 of 8873 (95th percentile). These high-percentile positions for infusion administration and extended-infusion add-ons suggest frequent, prolonged in‑office infusion sessions are a material part of how care is delivered and reimbursed.

Clinical evaluation-and-management activity generates a small share of Medicare revenue relative to biologics: 99214 accounts for $44.1K (2.1% of Medicare revenue) and 99213 for $4.7K (0.2%). This imbalance indicates the practice’s financial model is drug- and infusion-centered, with visit-level E/M billing representing a minor component of reported Medicare receipts.

The provider has an established tenure in Medicare billing, with an NPI enumerated on 2006-03-28 (~20 years ago), which supports an interpretation of long-standing local market presence and operational continuity. That longevity combined with very high drug-administration volumes suggests an experienced infusion service line rather than a recent program expansion.

The heavy reliance on a few biologic drugs creates strategic sensitivity: with 79.1% of Medicare revenue tied to the top three codes and J1745 explicitly billed as the non‑biosimilar infliximab formulation, the provider’s revenue could be materially affected by shifts in drug selection, biosimilar uptake, or payer coverage changes. Additionally, having no Medicaid billing on file means the practice lacks Medicaid diversification and is exposed to Medicare policy or market shifts without offset from state‑payer volumes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

23 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	25,650	$30	$872.1K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	21,800	$30	$566.8K
J3262	Injection, tocilizumab, 1 mg	62,040	$1	$248.2K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	43,600	$1	$174.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	10,600	$10	$116.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	520	$90	$45.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	500	$90	$44.1K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	490	$50	$22.4K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	560	$20	$10.7K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	40	$160	$6.6K

Showing 1–10 of 23

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 23 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Akgun Ince — 7 of 23 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

23 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	4	20	10,880	$30	$443.6K
J1602	14	20	13,150	$10	$266.8K
J0717	10	10	61,500	$1	$259.7K
J3262	6	10	40,980	$1	$236.8K
J1745	1	40	3,060	$30	$118.1K
96413	17	160	140	$100	$19.1K
99214	704	8,960	100	$80	$13.9K
99213	3,990	8,730	70	$50	$7K
99204	2,244	4,360	30	$100	$4.8K
99205	260	1,010	20	$140	$4.7K

Showing 1–10 of 23

Related Providers

Other providers that share a Tax Identification Number (TIN) with Akgun Ince, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Amanda Dehlendorf	MO	Internal Medicine Physician	$970.8K	$0
Joseph Stauber	MO	Rheumatology Physician	$374.6K	$0
Leanna Scheidemantel	MO	Nurse Practitioner	$38.2K	$0
Elaine Zobrist	MO	Adult Health Nurse Practitioner	$37.5K	$0

Nearby Providers

Other providers in the same ZIP code as Akgun Ince, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mercy Hospitals East Communities	MO	General Acute Care Hospital	$0	$56.5M
Bayada Home Health Care, Inc.	MO	Home Health Agency	$0	$41.2M
Mercy Clinic East Communities	MO	Internal Medicine Physician	$0	$22.2M
Excel Home Care, Inc.	MO	Home Health Agency	$0	$19.8M
Biotech X-ray Inc	MO	Portable X-ray and/or Other Portable Diagnostic Imaging Supplier	$5.1M	$6M
Western Anesthesiology Associates, Inc.	MO	Anesthesiology Physician	$0	$10.9M
Team Select Home Care Of Missouri, Inc.	MO	Nursing Care Agency	$0	$10.7M
Physician Groups Lc	MO	Multi-Specialty Clinic/Center	$0	$9.8M
Sensory Solutions, LLC	MO	Occupational Therapist	$0	$7.3M
Excel Home Care, Inc.	MO	Home Health Agency	$0	$6.2M

Akgun Ince — Billing Profile & Reimbursement Data

Sign up for Akgun Ince — Billing Profile & Reimbursement Data policy alerts

Akgun Ince — Billing Profile & Reimbursement Data

Sign up for Akgun Ince — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References